上海莱士(002252) - 2025 Q2 - 季度财报

Section I Important Notice, Table of Contents, and Definitions Important Notice The Board guarantees report accuracy, highlights key risks, and confirms no dividend distribution or capital reserve conversion. - The Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the report content[4] - The report's forward-looking statements are based on current conditions, do not constitute substantive commitments, and caution investors about risks including raw material supply, rising plasma costs, product safety, and goodwill impairment[5] - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[6] Table of Contents This section presents the complete report directory, comprising nine main chapters covering company profile, management discussion, corporate governance, significant matters, share changes, bond information, financial reports, and other submitted data. - The report directory includes nine main chapters, ranging from the company profile to financial reports and other submitted data[8] Reference Documents This section lists reference documents including the full text of the 2025 semi-annual report, financial statements, original announcements, and all documents publicly disclosed on designated media and websites. - Reference documents include the full report signed by the legal representative, financial statements, original disclosure documents from designated media, and other materials[10] Definitions This section defines common terms and company names used in the report, including regulatory bodies, exchanges, the company itself, major related parties (e.g., Haier Group, Grifols), and key product names. - The definitions section clarifies regulatory bodies, exchanges, company names, major related parties (e.g., Haier Group, Grifols), and product names mentioned in the report[12] Section II Company Profile and Key Financial Indicators 1. Company Profile Shanghai RAAS Blood Products Co., Ltd. is listed on the Shenzhen Stock Exchange under stock code "002252", with Jun Xu as its legal representative. Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Shanghai RAAS | | Stock Code | 002252 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Jun Xu (徐俊) | 2. Contact Persons and Information The company's Board Secretary is Liu Zheng and Securities Affairs Representative is Qiu Hong, both sharing the same contact address, phone, fax, and email. Company Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Liu Zheng | No. 2009 Wangyuan Road, Fengxian District, Shanghai | 021-22130888-217 | 021-37515869 | raas@raas-corp.com | | Securities Affairs Representative | Qiu Hong | No. 2009 Wangyuan Road, Fengxian District, Shanghai | 021-22130888-217 | 021-37515869 | raas@raas-corp.com | 3. Other Information The company's registered address, office address, website, email, and information disclosure locations remained unchanged during the reporting period. - The company's registered address, office address, website, email, and other contact information remained unchanged during the reporting period[16] - Information disclosure and filing locations remained unchanged during the reporting period[17] 4. Key Accounting Data and Financial Indicators In H1 2025, revenue decreased by 7.06% to 3.95 billion yuan, and net profit attributable to shareholders fell by 17.00% to 1.03 billion yuan, while operating cash flow significantly improved to 739 million yuan. Key Accounting Data and Financial Indicators (H1 2025 vs. Prior Year Period) | Indicator | Current Period (RMB) | Prior Year Period (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 3,952,191,668.60 | 4,252,338,864.23 | -7.06% | | Net Profit Attributable to Shareholders of Listed Company | 1,029,892,162.06 | 1,240,798,423.17 | -17.00% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains/Losses) | 1,040,256,033.97 | 1,128,729,566.55 | -7.84% | | Net Cash Flow from Operating Activities | 739,253,135.43 | -47,549,432.62 | N/A | | Basic Earnings Per Share (RMB/share) | 0.155 | 0.187 | -17.11% | | Diluted Earnings Per Share (RMB/share) | 0.155 | 0.187 | -17.11% | | Weighted Average Return on Net Assets | 3.19% | 4.10% | Decrease of 0.91 percentage points | | End of Current Period vs. End of Prior Year | | | | | Total Assets | 38,135,693,552.05 | 33,631,225,254.06 | 13.39% | | Net Assets Attributable to Shareholders of Listed Company | 32,408,939,858.40 | 31,926,258,696.02 | 1.51% | 5. Accounting Data Differences Under Domestic and International Accounting Standards The company reported no differences in net profit and net assets between international/overseas accounting standards and Chinese accounting standards. - The company has no accounting data differences under domestic and international accounting standards[20] 6. Non-Recurring Gains and Losses Items and Amounts The company's total non-recurring gains and losses amounted to -10.36 million yuan, primarily from non-current asset disposal, government grants, and other non-operating income/expenses. Non-Recurring Gains and Losses Items and Amounts | Item | Amount (RMB) | | :--- | :--- | | Gains or losses on disposal of non-current assets (including the write-off portion of asset impairment provisions) | 48,613.79 | | Government grants recognized in current profit or loss (excluding those closely related to the company's ordinary activities, compliant with national policies, enjoyed according to fixed standards, and with a sustained impact on the company's profit or loss) | 2,764,083.85 | | Other non-operating income and expenses apart from the above | -14,848,742.71 | | Less: Income tax impact | -1,680,496.01 | | Impact on minority interests (after tax) | 8,322.85 | | Total | -10,363,871.91 | Section III Management Discussion and Analysis 1. Main Business Activities During the Reporting Period The company produces and sells blood products, distributes Grifols' imports, and advances innovative drug R&D, with coagulation factor sales and plasma collection growing. (I) Company's Main Business The company's main business is the production and sale of blood products, including albumin, immunoglobulins, and coagulation factors, and it also exclusively distributes Grifols' imported albumin and blood screening products. - The company's main business is the production and sale of blood products, making it one of China's largest blood product manufacturers[24] - Key products include human albumin, intravenous human immunoglobulin, specific human immunoglobulin, and coagulation factor products[24] - The company exclusively distributes imported human albumin and blood screening related products from its related party, Grifols[24] (II) Company's Main Products and Uses The company produces three major categories of blood products—albumin, immunoglobulin, and coagulation factors—totaling up to nine products, essential for medical emergencies and specific disease treatments. Product Categories and Quantities of the Company and its Subsidiaries | Product Category | Product Name | Shanghai RAAS | Zhengzhou RAAS | Tonglu Bio | Zhejiang Haikang | Guangxi RAAS | Nanyue Bio | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Albumin Products | Human Albumin | √ | √ | √ | √ | √ | √ | | Immunoglobulin Products | Human Immunoglobulin | | √ | √ | √ | √ | √ | | | Intravenous Human Immunoglobulin (pH4) | √ | √ | √ | √ | √ | √ | | | Lyophilized Intravenous Human Immunoglobulin (pH4) | | | √ | | | | | | Hepatitis B Human Immunoglobulin | | √ | √ | √ | | √ | | | Tetanus Human Immunoglobulin | | | √ | |